|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Borderline Personality Disorder | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Disease | |||||
| Personality Disorders | |||||
| Self Mutilation | |||||
| 3 | More general conditions related to this trial | ||||
| Behavioral Symptoms | |||||
| Disorders of Environmental Origin | |||||
| Mental Disorders | |||||
| Pathologic Processes | |||||
| Self-Injurious Behavior | |||||
| Wounds and Injuries | |||||
| 4 | Interventions listed in this trial | ||||
| Fluoxetine | |||||
| Dialectical behavior therapy | |||||
| Supportive psychotherapy | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antidepressive Agents | |||||
| Antidepressive Agents, Second-Generation | |||||
| Central Nervous System Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Neurotransmitter Uptake Inhibitors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Psychotropic Drugs | |||||
| Serotonin Agents | |||||
| Serotonin Uptake Inhibitors | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||